Tectonic Therapeutic, Inc. (TECX): Cash & Equivalents
$253.80M
As of 2025-12-31
$227.07M
As of 2026-06-30
+40.0%
3-year compound annual growth
-0.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $253.80M | +79.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $141.24M | +390.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $28.77M | -68.9% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $92.56M | -51.2% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $189.57M | -27.0% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $259.68M | +38.8% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $187.04M | +48.1% | 2021-03-18, Balance as of period end |
| 2018-12-31 | $126.30M | n/m | 2020-03-16, Balance as of period end |
| 2017-12-31 | $5.96M | n/a | 2019-03-25, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $253.80M | +79.7% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $88.88M | -29.5% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $63.00M | +79.9% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $194.17M | +498.2% |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗